Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
Lucy MeunierMohamed BelkacemiGeorge Philippe PageauxSylvie RadenneAnaïs Vallet-PichardPauline Houssel-DebryChristophe DuvouxDanielle Botta-FridlundVictor de LedinghenFilomena ContiRodolphe AntyVincent Di MartinoMarilyne Debette-GratienVincent LeroyTheophile GersterPascal LebrayLaurent AlricArmando AbergelJérôme DumortierCamille BeschHelene MontialouxDidier SamuelJean-Charles Duclos-ValléeAudrey CoillyPublished in: Viruses (2022)
DAAs are safe and effective in patients awaiting LT for cirrhosis or HCC. A quarter of patients with cirrhosis can be delisted because of clinical improvement. Predictive factors for delisting, as a result of improvement, may assist prescribers, before initiating HCV infection therapy in the long-term perspective.